https://www.avient.com/news/specialty-and-sustainable-healthcare-material-solutions-avient-medtec-china-2023
Materials used for medical devices, labware, and pharmaceutical packaging play an important role in achieving more effective diagnostics and treatments for patients,” says Say-Eng Lee, vice president and general manager, Color & Additives Asia at Avient.
https://www.avient.com/news/medtec-china-2024-avient-announces-healthcare-tpu-manufacturing-expansion
It meets FDA and ISO 109931 standards for sulfone products and can be effective across a range of high-temperature polymers, including PEEK, PPSU, PES, PSU, PEI, LCP, and PPS, with a maximum service temperature exceeding 150°C.
https://www.avient.com/news/avient-present-broad-array-innovative-and-sustainable-materials-solutions-chinaplas-2025
At Avient, we’re committed to helping the plastics industry follow the latest regulations while enhancing product performance and making manufacturing more cost-effective," says Say-Eng Lee, Vice President and General Manager, Color & Additives Asia at Avient.
https://www.avient.com/news/polyone-acquires-magenta-master-fibers
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: unexpected costs that may arise from the announced acquisition of the Magenta business; any material adverse changes in the acquired Magenta business; our ability to achieve the strategic and other objectives relating to the acquired Magenta business, including any expected synergies; our ability to successfully integrate the acquired Magenta business and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive; our ability to realize anticipated savings and operational benefits from the realignment of assets, including the closure of manufacturing facilities; the timing of closings and shifts of production to new facilities related to asset realignments and any unforeseen loss of customers and/or disruptions of service or quality caused by such closings and/or production shifts; separation and severance amounts that differ from original estimates; amounts for non-cash charges related to asset write-offs and accelerated depreciation realignments of property, plant and equipment, that differ from original estimates; our ability to identify and evaluate acquisition targets and consummate acquisitions; the ability to successfully integrate acquired companies into our operations, retain the management teams of acquired companies and retain relationships with customers of acquired companies including, without limitation, Spartech Corporation and/or Accella Performance Materials; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; the speed and extent of an economic recovery, including the recovery of the housing market; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding the disposal of plastic in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; an inability to maintain appropriate relations with unions and employees; our ability to continue to pay cash dividends; the amount and timing of repurchases of our common shares, if any; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.
https://www.avient.com/news/polyone-expands-healthcare-portfolio-biomerics’-specialty-medical-solutions
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: the final amount of charges resulting from the planned North American asset realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment; our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies; our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; the speed and extent of an economic recovery, including the recovery of the housing market; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; an inability to maintain appropriate relations with unions and employees; the inability to achieve expected results from our acquisition activities; our ability to continue to pay cash dividends; the amount and timing of repurchases of our common shares, if any; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.
https://www.avient.com/sites/default/files/2021-04/avient-q4-earnings-and-2021-outlook-website.pdf
In addition, operating income before the effect of special items is a component of Avient’s annual and long-term employee incentive plans and is used in debt covenant computations.
Senior management believes the measures described above are useful to investors because they allow for comparison to Avient's performance in prior periods without the effect of items that, by their nature, tend to obscure Avient's operating results due to the potential variability across periods based on timing, frequency and magnitude.
A reconciliation of these measures to their most directly comparable GAAP measures is provided in the tables below. 1 Reconciliation of EBITDA by Segment Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Sales: Color, Additives and Inks $ 525.8 $ 226.7 $ 1,502.9 $ 1,003.8 Specialty Engineered Materials 190.6 177.5 708.8 745.7 Distribution 305.1 272.4 1,110.3 1,192.2 Corporate and eliminations (24.5) (18.0) (79.9) (79.0) Sales $ 997.0 $ 658.6 $ 3,242.1 $ 2,862.7 Operating income: Color, Additives and Inks $ 57.5 $ 27.2 $ 180.8 $ 147.4 Specialty Engineered Materials 30.4 18.8 94.4 83.7 Distribution 18.0 17.0 69.5 75.4 Corporate and eliminations (40.9) (42.5) (155.4) (149.7) Operating Income $ 65.0 $ 20.5 $ 189.3 $ 156.8 Items Below Operating Income in Corporate: Other income, net $ 11.7 $ 10.7 $ 24.3 $ 12.1 Depreciation & amortization: Color, Additives and Inks $ 27.3 $ 10.7 $ 75.1 $ 42.7 Specialty Engineered Materials 7.4 7.0 30.0 29.5 Distribution 0.3 0.1 0.7 0.5 Corporate and eliminations 2.8 1.0 9.3 5.4 Depreciation & Amortization $ 37.8 $ 18.8 $ 115.1 $ 78.1 EBITDA: Color, Additives and Inks $ 84.8 $ 37.9 $ 255.9 $ 190.1 Specialty Engineered Materials 37.8 25.8 124.4 113.2 Distribution 18.3 17.1 70.2 75.9 Corporate and eliminations (26.4) (30.8) (121.8) (132.2) EBITDA $ 114.5 $ 50.0 $ 328.7 $ 247.0 EBITDA as a % of sales: Color, Additives and Inks 16.1 % 16.7 % 17.0 % 18.9 % Specialty Engineered Materials 19.8 % 14.5 % 17.6 % 15.2 % Distribution 6.0 % 6.3 % 6.3 % 6.4 % Corporate and eliminations nm nm nm nm Total Company 11.5 % 7.6 % 10.1 % 8.6 % nm - not meaningful 2 Three Months Ended December 31, Year Ended December 31, Reconciliation to Adjusted EBITDA: 2020 2019 2020 2019 Net income from continuing operations – GAAP $ 74.7 $ 6.4 $ 133.8 $ 75.7 Income tax expense (17.3) 12.9 5.2 33.7 Interest expense 19.3 11.9 74.6 59.5 Depreciation and amortization from continuing operations 37.8 18.8 115.1 78.1 EBITDA $ 114.5 $ 50.0 $ 328.7 $ 247.0 Special items, before tax 4.2 15.0 66.2 61.7 Interest expense included in special items — — (10.1) — Accelerated depreciation included in special items (0.7) — (3.2) — Adjusted EBITDA $ 118.0 $ 65.0 $ 381.6 $ 308.7 Three Months Ended December 31, 2020 Reconciliation of Adjusted Earnings per Share: Avient Special Items Adjusted Avient Sales $ 997.0 $ — $ 997.0 Operating income $ 65.0 $ 14.6 $ 79.6 Interest expense, net (19.3) — (19.3) Other income, net 11.7 (10.4) 1.3 Income taxes 17.3 (30.9) (13.6) Net income from continuing operations attributable to Avient shareholders $ 74.2 $ (26.7) $ 47.5 Weighted average diluted shares 92.1 Adjusted EPS - excluding special items $ 0.52 Reconciliation of Adjusted EBITDA from continuing operations: Operating income and other income, net $ 76.7 $ 4.2 $ 80.9 Depreciation and amortization 37.8 (0.7) 37.1 EBITDA from continuing operations $ 114.5 $ 3.5 $ 118.0 EBITDA as a % of sales 11.8 % 3 Three Months Ended December 31, 2019 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 658.6 $ — $ 658.6 $ 263.5 $ 922.1 Operating income $ 20.5 $ 24.6 $ 45.1 $ 13.2 $ 58.3 Interest expense, net (11.9) — (11.9) (11.1) (23.0) Other income, net 10.7 (9.6) 1.1 — 1.1 Income taxes (12.9) 4.9 (8.0) (0.5) (8.5) Net income from continuing operations attributable to Avient shareholders $ 6.4 $ 19.9 $ 26.3 $ 1.6 $ 27.9 Weighted average diluted shares 77.5 Impact to diluted shares from January 2020 equity offering 15.3 Pro forma weighted average diluted shares 92.8 Pro forma adjusted EPS $ 0.30 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 31.2 $ 15.0 $ 46.2 $ 13.2 $ 59.4 Depreciation and amortization 18.8 — 18.8 15.1 33.9 EBITDA from continuing operations $ 50.0 $ 15.0 $ 65.0 $ 28.3 $ 93.3 EBITDA as a % of sales 10.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Year Ended December 31, 2020 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 3,242.1 $ — $ 3,242.1 $ 540.4 $ 3,782.5 Operating income $ 189.3 $ 73.7 $ 263.0 $ 45.0 $ 308.0 Interest expense, net (74.6) 10.1 (64.5) (18.1) (82.6) Other income, net 24.3 (17.6) 6.7 — 6.7 Income taxes (5.2) (41.4) (46.6) (6.2) (52.8) Net income attributable to noncontrolling interests (1.8) — (1.8) — (1.8) Net income from continuing operations attributable to Avient shareholders $ 132.0 $ 24.8 $ 156.8 $ 20.7 $ 177.5 Weighted average diluted shares 90.6 Impact to diluted shares from January 2020 equity offering 1.5 Pro forma weighted average diluted shares 92.1 Pro forma adjusted EPS $ 1.93 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 213.6 $ — $ 56.1 $ 269.7 $ 45.0 $ — $ 314.7 Depreciation and amortization 115.1 (3.2) 111.9 30.1 142.0 EBITDA from continuing operations $ 328.7 $ 52.9 $ 381.6 $ 75.1 $ 456.7 EBITDA as a % of sales 12.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition 4 Year Ended December 31, 2019 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 2,862.7 $ — $ 2,862.7 $ 1,118.6 $ 3,981.3 Operating income $ 156.8 $ 71.7 $ 228.5 $ 72.9 $ 301.4 Interest expense, net (59.5) — (59.5) (33.4) (92.9) Other income, net 12.1 (10.0) 2.1 — 2.1 Income taxes (33.7) (5.9) (39.6) (9.1) (48.7) Net income attributable to noncontrolling interests (0.2) — (0.2) — (0.2) Net income from continuing operations attributable to Avient shareholders $ 75.5 $ 55.8 $ 131.3 $ 30.4 $ 161.7 Weighted average diluted shares 77.7 Impact to diluted shares from January 2020 equity offering 15.3 Pro forma weighted average diluted shares 93.0 Pro forma adjusted EPS $ 1.74 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 168.9 $ — $ 61.7 $ 230.6 $ 72.9 $ — $ 303.5 Depreciation and amortization 78.1 — 78.1 60.3 138.4 EBITDA from continuing operations $ 247.0 $ 61.7 $ 308.7 $ 133.2 $ 441.9 EBITDA as a % of sales 11.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Three Months Ended March 31, 2020 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 711.5 $ — $ 711.5 $ 279.4 $ 990.9 Operating income 52.8 9.7 62.5 23.0 85.5 Interest expense, net (9.4) — (9.4) (12.8) (22.2) Other income, net 1.6 (0.1) 1.5 — 1.5 Income taxes (11.9) (1.0) (12.9) (2.4) (15.3) Net income from continuing operations attributable to Avient shareholders $ 33.1 $ 8.6 $ 41.7 $ 7.8 $ 49.5 Weighted average diluted shares 86.7 Impact to diluted shares from January 2020 equity offering 6.1 Pro forma weighted average diluted shares 92.8 Pro forma adjusted EPS $ 0.53 (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition 5 Three Months Ended December 31, 2019 Year Ended December 31, 2019 Reconciliation of pro forma sales, operating income, and EBITDA: CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI Sales $ 226.7 $ 263.5 $ 490.2 $ 1,003.8 $ 1,118.6 $ 2,122.4 Operating income $ 27.2 $ 13.2 $ 40.4 $ 147.4 $ 72.9 $ 220.3 EBITDA $ 37.9 $ 28.3 $ 66.2 $ 190.1 $ 133.2 $ 323.3 EBITDA as a % of sales 13.5 % 15.2 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Year Ended December 31, 2020 Reconciliation of pro forma sales, operating income, and EBITDA: CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI Sales $ 1,502.9 $ 540.4 $ 2,043.3 Operating income $ 180.8 $ 45.0 $ 225.8 EBITDA $ 255.9 $ 75.1 $ 331.0 EBITDA as a % of sales 16.2 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Free cash flow, defined as cash provided by operating activities excluding items associated with acquisitions and divestitures, less capital expenditures, is considered a non-GAAP financial measure.
https://www.avient.com/sites/default/files/2023-10/Flexi-StiX FlexSpring Case Study.pdf
According to Gordon, carbon fiber, despite its energy-returning effects, is not as friendly as fiberglass for a runner’s muscles, tendons, and joints.
Using the lessons learned from the outer sole development, Gordon and Jeff set out to find a fiberglass-reinforced material for the shoe insole application that embodied the energy-returning effects of carbon fiber while also demonstrating the flexibility needed to preserve and support the body and muscles of the runner.
https://www.avient.com/sites/default/files/2023-05/MagIQ Nonwoven Electret Additives Application Bulletin.pdf
In order to ensure the middle layer in a face mask can effectively block up to 95% of airborne particles, the material requires the addition of a specific additive prior to the meltblown stage followed by a process known as electret charging.
Charging only works when the correct additive solution is utilized, and together with the fiber denier, gram weight and number of layers, it ensures the middle layer of protective masks can effectively trap small airborne particles.
https://www.avient.com/sites/default/files/2023-08/EVSE Industry Bulletin.pdf
Custom formulations can also be developed using Smartbatch™ Combination Colorants & Additives, combining colors and effects with functionality to meet specific requirements.
This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner. 1.844.4AVIENT www.avient.com ADDITIVE TECHNOLOGIES Flame retardant additives Mitigates fire hazard by reducing flame spread and heat release Anti-static and conductive additives Controls build-up of static charges to reduce risk of fire and enhance safety Antimicrobial technology Reduces bacterial, mold and fungal growth on the surface and through the thickness of the part Light spectrum management Provides UV protection to prevent discoloration or degradation of mechanical properties for lasting outdoor durability and color fastness Scratch and mar resistant additives Adds protection to stand up to surface abrasion and wear and tear COLORANT TECHNOLOGIES UL 94 colorants Over 2,000 UL 94-recognized color concentrates, including for high temperature resins Special effect colorants Visual enhancements including metallic, granite, or pearlescent appearance Bio colorants and additives For use in bio-based plastics without compromising performance TECHNOLOGIES AVAILABLE TO ENHANCE PUBLIC CHARGING STATIONS Avient supports all of these solutions with a range of world-class services, including: • Polymer material expertise with a focus on sustainability • Application development expertise with global design centers • Regulatory compliance coordination to help mitigate risk • Reliable field technical services and support • Leading color trend and design services
https://www.avient.com/sites/default/files/2023-03/ColorMatrix Amosorb rPET Booster Product Bulletin.pdf
For brand owners seeking to maximize their rPET usage up to 100% to achieve sustainability and recyclability targets, Amosorb 4020R offers a cost effective solution with reliable oxygen scavenging performance and low haze levels on final bottles.
For converters manufacturing bottles for oxygen sensitive beverages such as juices or teas and sauces, Amosorb 4020R is a unique masterbatch solution offering a reliable, cost effective oxygen scavenging performance, while giving freedom of usage for many different grades of rPET up to 100% in content.